Affiliation:
1. Department of Pharmaceutical Chemistry Faculty of Pharmacy Gazi University Ankara Türkiye
2. Department of Pharmaceutical Chemistry Faculty of Pharmacy Suleyman Demirel University Isparta Türkiye
3. Department of Biochemistry Faculty of Pharmacy Suleyman Demirel University Isparta Türkiye
Abstract
AbstractIn our quest to develop new treatments for cancer, we synthesized and tested a series of urea‐functionalized aminothiazole‐benzazole analogs. Our primary focus was assessing their ability to inhibit the growth of breast cancer (MCF‐7) and lung adenocarcinoma (A549) cells. Using 1H NMR, 13C NMR spectra, and high resolution mass spectrometry (HRMS), we confirmed the chemical structures of these compounds. Among them, compound 8a demonstrated significant cytotoxicity against MCF‐7 cells, achieving an IC50 value of 9.6±0.6 μM. Similarly, compound 8e exhibited potent cytotoxicity against A549 cells, with an IC50 value of 9.2±1.1 μM. We further investigated the antimigration properties of all compounds that showed promising antiproliferative effects in both MCF‐7 and A549 cells. Additionally, we evaluated how these compounds impact key apoptosis‐related proteins: Caspase‐7, PARP‐1, BAX, and Bcl‐2. These proteins play crucial roles in the regulation of programmed cell death. Overall, our findings suggest that these urea‐functionalized aminothiazole‐benzazole analogs hold promise as potential anticancer agents, warranting further exploration into their mechanisms of action and therapeutic potential.